Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils

References

• Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet 1993 Apr 2,4; 341(8852):1065–9; http://dx.doi.org/10.1016/0140-6736(93)92422-P
   PubMed Web of Science ®Google Scholar
• Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfält R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002 Jun; 33(6):483–91; PMID:12001283; http://dx.doi.org/10.1002/ppul.10100
   PubMed Web of Science ®Google Scholar
• Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002 Aug; 34(2):91–100; PMID:12112774; http://dx.doi.org/10.1002/ppul.10127
   PubMed Web of Science ®Google Scholar
• Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997 May; 23:330–5; PMID:9168506; http://dx.doi.org/10.1002/(SICI)1099-0496(199705)23:5%3c330::AID-PPUL4%3e3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008 Nov; 7:523–30; PMID:18693078; http://dx.doi.org/10.1016/j.jcf.2008.06.009
   PubMed Web of Science ®Google Scholar
• Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005 Sep; 26:458–61; PMID:16135728; http://dx.doi.org/10.1183/09031936.05.00009605
   PubMed Web of Science ®Google Scholar
• Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003 Mar 15; 167:841–9; http://dx.doi.org/10.1164/rccm.200208-855OC
   PubMed Web of Science ®Google Scholar
• Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012 Dec; 11:461–79; PMID:23137712; http://dx.doi.org/10.1016/j.jcf.2012.10.004
   PubMed Web of Science ®Google Scholar
• Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, EPIC Investigators. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012 Feb; 47:125–34; PMID:21830317; http://dx.doi.org/10.1002/ppul.21525
   PubMed Web of Science ®Google Scholar
• Ho SA, Lee TW, Denton M, Conway SP, Brownlee KG. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J Cyst Fibros 2009 Jan; 8:43–6; PMID:18829398; http://dx.doi.org/10.1016/j.jcf.2008.08.001
   PubMed Web of Science ®Google Scholar
• Bosso JA, Allen JE, Matsen JM. Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics. Antimicrob Agents Chemother 1989 Apr; 33:526–8; PMID:2499252; http://dx.doi.org/10.1128/AAC.33.4.526
   PubMed Web of Science ®Google Scholar
• Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993 Jun; 31:919–26; PMID:8360129; http://dx.doi.org/10.1093/jac/31.6.919
   PubMed Web of Science ®Google Scholar
• Ciofu O, Giwercman B, Pedersen SS, Høiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 1994 Sep; 102:674–80.
   PubMed Web of Science ®Google Scholar
• Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 2010 Jul; 65:654–8.; http://dx.doi.org/10.1136/thx.2009.131532
   PubMed Web of Science ®Google Scholar
• Parmar JS, Nasser S. Antibiotic allergy in cystic fibrosis. Thorax 2005 Jun; 60:517–20; PMID:15923254; http://dx.doi.org/10.1136/thx.2004.027953
   PubMed Web of Science ®Google Scholar
• Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000 Oct; 13:602–14; PMID:11023960; http://dx.doi.org/10.1128/CMR.13.4.602-614.2000
   PubMed Web of Science ®Google Scholar
• Nilsson E, Larsson A, Olesen HV, Wejåker PE, Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol 2008 Sep; 43:892–9; PMID:18680179; http://dx.doi.org/10.1002/ppul.20875
   PubMed Web of Science ®Google Scholar
• Warr GW, Magor KE, Higgins DA. IgY: clues to the origins of modern antibodies. Immunol Today 1995 Aug; 16:392–8; PMID:7546196; http://dx.doi.org/10.1016/0167-5699(95)80008-5
   PubMedGoogle Scholar
• Patterson R, Youngner JS, Weigle WO, Dixon FJ. Antibody production and transfer to egg yolk in chickens. J Immunol 1962 Aug; 89:272–8; PMID:14484407
   PubMed Web of Science ®Google Scholar
• Rose ME, Orlans E, Buttress N. Immunoglobulin classes in the hen's egg: their segregation in yolk and white. Eur J Immunol 1974 Jul; 4:521–3; PMID:4213170; http://dx.doi.org/10.1002/eji.1830040715
   PubMed Web of Science ®Google Scholar
• Bhanushali JK, Gilbert JM, McDougald LR. Simple method to purify chicken immunoglobulin G. Poult Sci 1994 Jul; 73:1158–61; PMID:7937478; http://dx.doi.org/10.3382/ps.0731158
   PubMed Web of Science ®Google Scholar
• Dias da Silva W, Tambourgi DV. IgY: a promising antibody for use in immunodiagnostic and in immunotherapy. Vet Immunol Immunopathol 2010 Jun 15; 135:173–80; PMID:20083313; http://dx.doi.org/10.1016/j.vetimm.2009.12.011
   PubMed Web of Science ®Google Scholar
• Carlander D, Sundstrom J, Berglund A, Larsson A, Wretlind B, Kollberg H. Immunoglobulin Y(IgY)-A new tool for the prophylaxis against Pseudomonas aeruginosa in cystic fibrosis patients. Pediatr Pulmonol Suppl 1999; 19:241.
   Google Scholar
• Nilsson E, Amini A, Wretlind B, Larsson A. Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856:75–80; PMID:17581799; http://dx.doi.org/10.1016/j.jchromb.2007.05.029
   PubMed Web of Science ®Google Scholar
• Jensen PØ, Moser C, Kobayashi O, Hougen HP, Kharazmi A, Høiby N. Faster activation of polymorphonuclear neutrophils in resistant mice during early innate response to Pseudomonas aeruginosa lung infection. Clin Exp Immunol 2004 Sep; 137:478–85.; http://dx.doi.org/10.1111/j.1365-2249.2004.02554.x
   PubMed Web of Science ®Google Scholar
• Zhen YH, Jin LJ, Guo J, Li XY, Li Z, Fang R, Xu YP. Characterization of specific egg yolk immunoglobulin (IgY) against mastitis-causing Staphylococcus aureus. J Appl Microbiol 2008 Nov; 105:1529–35; PMID:19146490; http://dx.doi.org/10.1111/j.1365-2672.2008.03920.x
   PubMed Web of Science ®Google Scholar
• Xu Y, Li X, Jin L, Zhen Y, Lu Y, Li S, You J, Wang L. Application of chicken egg yolk immunoglobulins in the control of terrestrial and aquatic animal diseases: a review. Biotechnol Adv 2011 Nov–Dec; 29:860–8; PMID:21787857; http://dx.doi.org/10.1016/j.biotechadv.2011.07.003
   PubMed Web of Science ®Google Scholar
• Hatta H, Tsuda K, Ozeki M, Kim M, Yamamoto T, Otake S, Hirasawa M, Katz J, Childers NK, Michalek SM. Passive immunization against dental plaque formation in humans: effect of a mouth rinse containing egg yolk antibodies (IgY) specific to Streptococcus mutans. Caries Res 1997; 31:268–74; PMID:9197932; http://dx.doi.org/10.1159/000262410
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Sugano N, Shimada T, Shofiqur RA, Ibrahim el-SM, Isoda R, Umeda K, Sa NV, Kodama Y, Ito K. Effects of egg yolk antibody against Porphyromonas gingivalis gingipains in periodontitis patients. J Oral Sci 2007 Sep; 49:201–6; http://dx.doi.org/10.2334/josnusd.49.201
   PubMedGoogle Scholar
• Takeuchi S, Motohashi J, Kimori H, Nakagawa Y, Tsurumoto A. Effects of oral moisturising gel containing egg yolk antibodies against Candida albicans in older people. Gerodontology 2014; http://dx.doi.org/10.1111/ger.12139
   PubMed Web of Science ®Google Scholar
• Horie K, Horie N, Abdou AM, Yang JO, Yun SS, Chun HN, Park CK, Kim M, Hatta H. Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans. J Dairy Sci 2004 Dec; 87:4073–9; PMID:15545368; http://dx.doi.org/10.3168/jds.S0022-0302(04)73549-3
   PubMed Web of Science ®Google Scholar
• Rahman S, Higo-Moriguchi K, Htun KW, Taniguchi K, Icatlo FC Jr, Tsuji T, Kodama Y, Van Nguyen S, Umeda K, Oo HN, et al. Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. Vaccine 2012 Jun 29; 30:4661–9; PMID:22575165; http://dx.doi.org/10.1016/j.vaccine.2012.04.091
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Peralta RC, Sendo S, Ikemori Y, Kodama Y. Detection of passage and absorption of chicken egg yolk immunoglobulins in the gastrointestinal tract of pigs by use of enzyme-linked immunosorbent assay and fluorescent antibody testing. Am J Vet Res 1993 Jun; 54:867–72; PMID:8323054
   PubMed Web of Science ®Google Scholar
• Carlander D, Kollberg H, Larsson A. Retention of specific yolk IgY in the human oral cavity. BioDrugs 2002; 16:433–7; PMID:12463766; http://dx.doi.org/10.2165/00063030-200216060-00004
   PubMed Web of Science ®Google Scholar
• Wallach MG, Webby RJ, Islam F, Walkden-Brown S, Emmoth E, Feinstein R, Gronvik KO. Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice. Clin Vaccine Immunol 2011 Jul; 18:1083–90; PMID:21613458; http://dx.doi.org/10.1128/CVI.05075-11
   PubMed Web of Science ®Google Scholar
• Nguyen HH, Tumpey TM, Park HJ, Byun YH, Tran LD, Nguyen VD, Kilgore PE, Czerkinsky C, Katz JM, Seong BL, et al. Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. PLoS One 2010 Apr 13; 5:e10152; PMID:20405007; http://dx.doi.org/10.1371/journal.pone.0010152
   PubMedGoogle Scholar
• Cheung DO, Halsey K, Speert DP. Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect Immun 2000 Aug; 68:4585–92; PMID:10899859; http://dx.doi.org/10.1128/IAI.68.8.4585-4592.2000
   PubMed Web of Science ®Google Scholar
• Anderson CL, Shen L, Eicher DM, Wewers MD, Gill JK. Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes. J Exp Med 1990 Apr 1; 171:1333–45; http://dx.doi.org/10.1084/jem.171.4.1333
   PubMed Web of Science ®Google Scholar
• Schreiner B, Viertlboeck BC, Göbel TW. A striking example of convergent evolution observed for the ggFcR:IgY interaction closely resembling that of mammalian FcR:IgG. Dev Comp Immunol 2012 Mar; 36:566–71; PMID:21986582; http://dx.doi.org/10.1016/j.dci.2011.09.013
   PubMed Web of Science ®Google Scholar
• Alexis NE, Muhlebach MS, Peden DB, Noah TL. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros 2006 Jan; 5:17–25. Epub 2005 Dec 13; http://dx.doi.org/10.1016/j.jcf.2005.11.001
   PubMed Web of Science ®Google Scholar
• Morris MR, Doull IJ, Dewitt S, Hallett MB. Reduced iC3b-mediated phagocytotic capacity of pulmonary neutrophils in cystic fibrosis. Clin Exp Immunol 2005 Oct; 142:68–75; http://dx.doi.org/10.1111/j.1365-2249.2005.02893.x
   PubMed Web of Science ®Google Scholar
• Painter RG, Valentine VG, Lanson NA Jr, Leidal K, Zhang Q, Lombard G, Thompson C, Viswanathan A, Nauseef WM, Wang G, et al. CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 2006 Aug 29; 45:10260–9; PMID:16922501; http://dx.doi.org/10.1021/bi060490t
   PubMed Web of Science ®Google Scholar
• Voglis S, Quinn K, Tullis E, Liu M, Henriques M, Zubrinich C, Peñuelas O, Chan H, Silverman F, Cherepanov V, et al. Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. Am J Respir Crit Care Med 2009 Jul 15; 180:159–66; PMID:19406984; http://dx.doi.org/10.1164/rccm.200808-1250OC
   PubMed Web of Science ®Google Scholar
• Del Porto P, Cifani N, Guarnieri S, Di Domenico EG, Mariggi∫ MA, Spadaro F, Guglietta S, Anile M, Venuta F, Quattrucci S, et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One 2011; 6:e19970; PMID:21625641; http://dx.doi.org/10.1371/journal.pone.0019970
   PubMed Web of Science ®Google Scholar
• McKeon DJ, Cadwallader KA, Idris S, Cowburn AS, Pasteur MC, Barker H, Haworth CS, Bilton D, Chilvers ER, Condliffe AM. Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation. Eur Respir J 2010 Jun; 35:1264–72; PMID:19840964; http://dx.doi.org/10.1183/09031936.00089709
   PubMed Web of Science ®Google Scholar
• Kollberg H, Carlander D, Olesen H, Wejåker PE, Johannesson M, Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 2003 Jun; 35:433–40; PMID:12746939; http://dx.doi.org/10.1002/ppul.10290
   PubMed Web of Science ®Google Scholar